Second, the CeTeG/NOA‐09 phase III trial demonstrated an increased median OS of 48.1 months in patients with MGMT‐methylated GBM receiving CCNU/TMZ, rendering this combined chemotherapy a treatment option selectively for patients belonging to this molecularly defined subgroup [33]. This evidence concerns the gene MGMT and glioblastoma.